ZA200908298B - Bicycloaniline derivative - Google Patents
Bicycloaniline derivativeInfo
- Publication number
- ZA200908298B ZA200908298B ZA200908298A ZA200908298A ZA200908298B ZA 200908298 B ZA200908298 B ZA 200908298B ZA 200908298 A ZA200908298 A ZA 200908298A ZA 200908298 A ZA200908298 A ZA 200908298A ZA 200908298 B ZA200908298 B ZA 200908298B
- Authority
- ZA
- South Africa
- Prior art keywords
- bicycloaniline
- derivative
- bicycloaniline derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007159217 | 2007-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200908298B true ZA200908298B (en) | 2010-08-25 |
Family
ID=40129803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200908298A ZA200908298B (en) | 2007-06-15 | 2009-11-24 | Bicycloaniline derivative |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8436004B2 (es) |
| EP (1) | EP2168966B1 (es) |
| JP (1) | JP5129812B2 (es) |
| KR (1) | KR20100024932A (es) |
| CN (1) | CN101784551A (es) |
| AU (1) | AU2008262837B2 (es) |
| CA (1) | CA2689429C (es) |
| CY (1) | CY1118448T1 (es) |
| DK (1) | DK2168966T3 (es) |
| ES (1) | ES2608940T3 (es) |
| HR (1) | HRP20161536T1 (es) |
| HU (1) | HUE032403T2 (es) |
| IL (1) | IL202262A0 (es) |
| LT (1) | LT2168966T (es) |
| MX (1) | MX2009013728A (es) |
| NZ (1) | NZ581936A (es) |
| PL (1) | PL2168966T3 (es) |
| PT (1) | PT2168966T (es) |
| RU (1) | RU2010101052A (es) |
| SI (1) | SI2168966T1 (es) |
| WO (1) | WO2008153207A1 (es) |
| ZA (1) | ZA200908298B (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011516494A (ja) * | 2008-04-07 | 2011-05-26 | ギリアード サイエンシーズ， インコーポレイテッド | ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための２Ｈ−ベンゾ［ｂ］［１，４］オキサジン−３（４Ｈ）−オン誘導体 |
| WO2009151997A1 (en) * | 2008-06-12 | 2009-12-17 | Merck & Co., Inc. | Process for producing bicycloaniline derivatives |
| AU2009325400A1 (en) * | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivatives |
| AU2009325398A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
| AU2010218781A1 (en) * | 2009-02-25 | 2011-07-28 | Msd K.K. | Pyrimidopyrimidoindazole derivative |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| WO2013039854A1 (en) | 2011-09-15 | 2013-03-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| CN103113311A (zh) * | 2012-07-19 | 2013-05-22 | 南京邮电大学 | 一类2-芳基喹唑啉或2-杂环芳基喹唑啉衍生物及其制备方法 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| CN105307657B (zh) | 2013-03-15 | 2020-07-10 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| CN104725333A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种新的氮杂环庚烷衍生物的制备方法 |
| JP2017517520A (ja) * | 2014-05-29 | 2017-06-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US10308656B2 (en) * | 2015-08-18 | 2019-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of Ku70/80 and uses thereof |
| US20180353464A1 (en) * | 2015-11-24 | 2018-12-13 | Indiana University Research And Technology Corporation | Composition for blocking angiogenesis |
| JP6883653B2 (ja) | 2016-12-20 | 2021-06-09 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用 |
| CN110678169A (zh) | 2017-03-31 | 2020-01-10 | 西雅图遗传学公司 | Chk1-抑制剂与weel-抑制剂的组合 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| AU2018347307A1 (en) * | 2017-10-09 | 2020-04-23 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| CN109810111B (zh) * | 2017-11-20 | 2023-10-27 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2020210377A1 (en) * | 2019-04-09 | 2020-10-15 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3952878A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| JP2022526831A (ja) | 2019-04-09 | 2022-05-26 | ニューベイション・バイオ・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN112442049A (zh) * | 2019-09-03 | 2021-03-05 | 微境生物医药科技(上海)有限公司 | 作为Wee1抑制剂的嘧啶衍生物 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4048277A1 (en) | 2019-10-25 | 2022-08-31 | Astrazeneca AB | Methods of treating cancer |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12551584B1 (en) | 2020-12-07 | 2026-02-17 | Actinium Pharmaceuticals, Inc. | Lewis Y radioimmunotherapy for the treatment of cancer |
| CN116888107B (zh) * | 2021-02-19 | 2026-04-21 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的稠环化合物 |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| KR20240004584A (ko) | 2021-04-29 | 2024-01-11 | 노파르티스 아게 | 탈유비퀴티나아제-표적화 키메라 및 관련된 방법 |
| KR20240004539A (ko) * | 2021-04-30 | 2024-01-11 | 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 | Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3253688A1 (en) | 2022-03-07 | 2023-09-14 | Debiopharm International S.A. | TREATMENT METHODS FOR SMALL CELL LUNG CANCER |
| WO2025056747A1 (en) | 2023-09-14 | 2025-03-20 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a pkmyt1 inhibitor |
| TW202541810A (zh) | 2023-12-22 | 2025-11-01 | 瑞士商德彪製藥國際公司 | 治療實體腫瘤之方法 |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200003429T2 (tr) * | 1998-05-26 | 2001-07-23 | Warner-Lambert Company | Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler. |
| AP2002002643A0 (en) * | 2000-03-06 | 2002-12-31 | Warner Lambert Co | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| TW200413381A (en) * | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
| MXPA05004370A (es) * | 2002-11-15 | 2005-07-26 | Basf Ag | Mezclas fungicidas para combatir patogenos de arroz. |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| TW200530235A (en) * | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
| FR2873118B1 (fr) * | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| CA2579406A1 (en) * | 2004-09-21 | 2006-03-30 | F.Hoffmann-La Roche Ag | 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors |
| US7930013B2 (en) | 2005-06-29 | 2011-04-19 | Compumedics Limited | Sensor assembly with conductive bridge |
| US7622463B2 (en) | 2006-02-14 | 2009-11-24 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
-
2008
- 2008-06-12 JP JP2009519343A patent/JP5129812B2/ja active Active
- 2008-06-12 AU AU2008262837A patent/AU2008262837B2/en active Active
- 2008-06-12 ES ES08777358.6T patent/ES2608940T3/es active Active
- 2008-06-12 MX MX2009013728A patent/MX2009013728A/es not_active Application Discontinuation
- 2008-06-12 DK DK08777358.6T patent/DK2168966T3/en active
- 2008-06-12 HU HUE08777358A patent/HUE032403T2/en unknown
- 2008-06-12 PT PT87773586T patent/PT2168966T/pt unknown
- 2008-06-12 CN CN200880103594A patent/CN101784551A/zh active Pending
- 2008-06-12 LT LTEP08777358.6T patent/LT2168966T/lt unknown
- 2008-06-12 EP EP08777358.6A patent/EP2168966B1/en active Active
- 2008-06-12 RU RU2010101052/04A patent/RU2010101052A/ru not_active Application Discontinuation
- 2008-06-12 US US12/663,729 patent/US8436004B2/en active Active
- 2008-06-12 NZ NZ581936A patent/NZ581936A/en unknown
- 2008-06-12 CA CA2689429A patent/CA2689429C/en active Active
- 2008-06-12 PL PL08777358T patent/PL2168966T3/pl unknown
- 2008-06-12 WO PCT/JP2008/061182 patent/WO2008153207A1/ja not_active Ceased
- 2008-06-12 HR HRP20161536TT patent/HRP20161536T1/hr unknown
- 2008-06-12 SI SI200831719A patent/SI2168966T1/sl unknown
- 2008-06-12 KR KR1020097026035A patent/KR20100024932A/ko not_active Withdrawn
-
2009
- 2009-11-22 IL IL202262A patent/IL202262A0/en unknown
- 2009-11-24 ZA ZA200908298A patent/ZA200908298B/xx unknown
-
2016
- 2016-12-27 CY CY20161101346T patent/CY1118448T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110135601A1 (en) | 2011-06-09 |
| EP2168966B1 (en) | 2016-09-28 |
| JP5129812B2 (ja) | 2013-01-30 |
| IL202262A0 (en) | 2010-06-16 |
| DK2168966T3 (en) | 2017-01-23 |
| LT2168966T (lt) | 2017-01-10 |
| AU2008262837A1 (en) | 2008-12-18 |
| CA2689429A1 (en) | 2008-12-18 |
| KR20100024932A (ko) | 2010-03-08 |
| NZ581936A (en) | 2011-08-26 |
| EP2168966A4 (en) | 2011-02-16 |
| PT2168966T (pt) | 2017-01-02 |
| PL2168966T3 (pl) | 2017-06-30 |
| CA2689429C (en) | 2012-08-21 |
| CY1118448T1 (el) | 2017-06-28 |
| HRP20161536T1 (hr) | 2016-12-30 |
| EP2168966A1 (en) | 2010-03-31 |
| US8436004B2 (en) | 2013-05-07 |
| ES2608940T3 (es) | 2017-04-17 |
| HUE032403T2 (en) | 2017-09-28 |
| RU2010101052A (ru) | 2011-07-20 |
| CN101784551A (zh) | 2010-07-21 |
| JPWO2008153207A1 (ja) | 2010-08-26 |
| SI2168966T1 (sl) | 2017-03-31 |
| WO2008153207A1 (ja) | 2008-12-18 |
| AU2008262837B2 (en) | 2013-05-23 |
| MX2009013728A (es) | 2010-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400041I1 (hu) | 4-Pirimidin-szulfamid-származék | |
| ZA200908298B (en) | Bicycloaniline derivative | |
| ZA201003631B (en) | Isoxazolo-pyridine derivatives | |
| IL205753A0 (en) | Isoxazolo-pyridazine derivatives | |
| IL202020A0 (en) | Spiroindolinone derivatives | |
| ZA201001058B (en) | Quinazolinamide derivatives | |
| IL202830A0 (en) | Indazolamide derivatives | |
| IL205755A0 (en) | Isoxazolo-pyrazine derivatives | |
| PT2336132E (pt) | Derivado de morfolinopurina | |
| IL200618A0 (en) | Aza-pyridopyrimidinone derivatives | |
| EP2269993A4 (en) | 2-aminoquinazoline DERIVATIVE | |
| ZA201005769B (en) | Bicycloamine derivative | |
| SI2275414T1 (sl) | Ciklopentilakrilamidni derivat | |
| IL202667A0 (en) | Isoxazole-imidazole derivatives | |
| EP2163554A4 (en) | PYRIMIDODIAZEPINONE DERIVATIVE | |
| PL2245028T3 (pl) | Pochodne 5-aminocyklilometyloksazolidyn-2-onu | |
| EP2133347A4 (en) | 1-BIARYLAZETIDINONDERIVATE | |
| IL202463A0 (en) | Sulfonyl-quinoline derivatives | |
| IL202159A0 (en) | Piperidine-amide derivatives | |
| IL212683A0 (en) | Biphenylacetamide derivative | |
| EP2228362A4 (en) | 4-HYDROXYPHENYLALKYLAMINE DERIVATIVE | |
| ZA201002218B (en) | Thiadiazinone derivatives | |
| ZA201000311B (en) | Sulfonyl-quinoline derivatives | |
| GB0702266D0 (en) | 7-Azaindoe derivatives | |
| AP2009005065A0 (en) | Sulfonyl-quinoline derivatives |